• 我要登录|
  • 免费注册
    |
  • 我的丁香通
    • 企业机构:
    • 成为企业机构
    • 个人用户:
    • 个人中心
  • 移动端
    移动端
丁香通 logo丁香实验_LOGO
搜实验

    大家都在搜

      大家都在搜

        0 人通过求购买到了急需的产品
        免费发布求购
        发布求购
        点赞
        收藏
        wx-share
        分享

        Hybrid Cell Vaccination in Patients With Metastatic Melanoma

        互联网

        622
        Hybrid cell vaccination is a novel approach for immunotherapy of cancers by inducing specific antitumor immunity (1 ,2 ). The hybrid cells are generated by electrofusing autologous tumor cells with allogeneic MHC class II expressing cells such as B lymphocytes. The fused cells are irradiated and injected subcutaneously as a vaccine. This immune therapeutical approach aims at recruitment of T-cell help for the induction of tumor-specific cytolytic immunity. It is based on the observation that epitope linkage is a prerequisite for productive T-T cell collaboration, i.e., cytolytic precursor and helper T cells have to be activated by the same antigen presenting cell that displays epitopes for both T-cell types on the corresponding MHC class I and class II molecules (3 ,4 ). Neither of the two epitopes nor the corresponding T cells need to be related. The implications of this concept are, first, only MHC class I and II expressing cells can induce cytolytic T-cell responses (5 -7 ), second, cognate antigens must be presented for both T-cell and MHC types (4 ,8 ) and, third, there must be T cells with the corresponding specificities in the T-cell receptor repertoire of the response-competent individual.
        ad image
        提问
        扫一扫
        丁香实验小程序二维码
        实验小助手
        丁香实验公众号二维码
        扫码领资料
        反馈
        TOP
        打开小程序